{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:38:49Z","timestamp":1778837929358,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T00:00:00Z","timestamp":1456704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40257-016-0179-3","type":"journal-article","created":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T10:15:28Z","timestamp":1456740928000},"page":"191-200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Novel Oral Therapies for Psoriasis and Psoriatic Arthritis"],"prefix":"10.1007","volume":"17","author":[{"given":"Zenas Z. N.","family":"Yiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,29]]},"reference":[{"issue":"2","key":"179_CR1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archderm.1958.01560080060010","volume":"78","author":"WF Edmundson","year":"1958","unstructured":"Edmundson WF, Guy WB. Treatment of psoriasis with folic acid antagonists. AMA Arch Dermatol. 1958;78(2):200\u20133.","journal-title":"AMA Arch Dermatol"},{"issue":"5","key":"179_CR2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2230.2008.02976.x","volume":"33","author":"RB Warren","year":"2008","unstructured":"Warren RB, Chalmers RJG, Griffiths CEM, Menter A. Methotrexate for psoriasis in the era of biological therapy. Clin Exp Dermatol. 2008;33(5):551\u20134.","journal-title":"Clin Exp Dermatol"},{"issue":"9583","key":"179_CR3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"CEM Griffiths","year":"2007","unstructured":"Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263\u201371.","journal-title":"Lancet"},{"issue":"1","key":"179_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/1744666X.2016.1112739","volume":"12","author":"ZZ Yiu","year":"2016","unstructured":"Yiu ZZ, Griffiths CE. Interleukin 17-A inhibition in the treatment of psoriasis. Expert Rev Clin Immunol. 2016;12(1):1\u20134.","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"179_CR5","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","volume":"135","author":"RB Warren","year":"2015","unstructured":"Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker JNWN, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632\u201340.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"179_CR6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaad.2014.11.028","volume":"72","author":"LS D\u2019Souza","year":"2015","unstructured":"D\u2019Souza LS, Payette MJ. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. J Am Acad Dermatol. 2015;72(4):589\u201398.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"179_CR7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatol Oxf Engl. 2011;50(1):124\u201331.","journal-title":"Rheumatol Oxf Engl"},{"issue":"9","key":"179_CR8","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","volume":"26","author":"PH Schafer","year":"2014","unstructured":"Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016\u201329.","journal-title":"Cell Signal"},{"issue":"4","key":"179_CR9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","volume":"159","author":"PH Schafer","year":"2010","unstructured":"Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842\u201355.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"179_CR10","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1185\/030079908X301866","volume":"24","author":"AB Gottlieb","year":"2008","unstructured":"Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008;24(5):1529\u201338.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"179_CR11","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52\u00a0weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387\u201399.","journal-title":"Br J Dermatol"},{"issue":"6","key":"179_CR12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"179_CR13","first-page":"355","volume":"74","author":"P Mease","year":"2015","unstructured":"Mease P, Adebajo A, Gladman D, Gomez-Reino J, Hall S, Kavanaugh A, et al. THU0432 long-term (104-week) safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: pooled safety analysis of three phase 3, randomized, controlled trials. Ann Rheum Dis. 2015;74(Suppl 2):355\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"179_CR14","first-page":"AB227","volume":"72","author":"K Reich","year":"2015","unstructured":"Reich K, Sobell J, Day RM, Stevens RM, Shah K. Change in weight with apremilast, an oral phosphodiesterase 4 inhibitor: pooled analysis of the ESTEEM 1 and ESTEEM 2 trials. J Am Acad Dermatol. 2015;72(5):AB227.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"179_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40744-014-0005-4","volume":"1","author":"PJ Mease","year":"2014","unstructured":"Mease PJ. Apremilast: a phosphodiesterase 4 inhibitor for the treatment of psoriatic arthritis. Rheumatol Ther. 2014;1(1):1\u201320.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"179_CR16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2133.2012.10835.x","volume":"166","author":"AD Burden","year":"2012","unstructured":"Burden AD, Warren RB, Kleyn CE, McElhone K, Smith CH, Reynolds NJ, et al. The British Association of Dermatologists\u2019 Biologic Interventions Register (BADBIR): design, methodology and objectives. Br J Dermatol. 2012;166(3):545\u201354.","journal-title":"Br J Dermatol"},{"key":"179_CR17","doi-asserted-by":"crossref","unstructured":"Chang BY, Zhao F, He X, Ren H, Braselmann S, Taylor V, et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL\/J mice. J Immunol Baltim Md 1950. 2009;183(3):2183\u201392.","DOI":"10.4049\/jimmunol.0804063"},{"issue":"5","key":"179_CR18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/exd.12128","volume":"22","author":"RM Andr\u00e9s","year":"2013","unstructured":"Andr\u00e9s RM, Hald A, Johansen C, Kragballe K, Iversen L. Studies of Jak\/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity. Exp Dermatol. 2013;22(5):323\u20138.","journal-title":"Exp Dermatol"},{"issue":"9993","key":"179_CR19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","volume":"386","author":"H Bachelez","year":"2015","unstructured":"Bachelez H, van de Kerkhof PCM, Strohal R, Kubanov A, Valenzuela F, Lee J-H, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552\u201361.","journal-title":"Lancet"},{"issue":"25","key":"179_CR20","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377\u201386.","journal-title":"N Engl J Med"},{"issue":"3","key":"179_CR21","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","volume":"167","author":"KA Papp","year":"2012","unstructured":"Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668\u201377.","journal-title":"Br J Dermatol"},{"issue":"7","key":"179_CR22","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.clinthera.2014.06.018","volume":"36","author":"K Kaur","year":"2014","unstructured":"Kaur K, Kalra S, Kaushal S. Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis. Clin Ther. 2014;36(7):1074\u201386.","journal-title":"Clin Ther"},{"issue":"1","key":"179_CR23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/08923973.2014.993084","volume":"37","author":"D D\u2019Ambrosio","year":"2015","unstructured":"D\u2019Ambrosio D, Steinmann J, Brossard P, Dingemanse J. Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations. Immunopharmacol Immunotoxicol. 2015;37(1):103\u20139.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"2","key":"179_CR24","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.110.176487","volume":"337","author":"L Piali","year":"2011","unstructured":"Piali L, Froidevaux S, Hess P, Nayler O, Bolli MH, Schlosser E, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther. 2011;337(2):547\u201356.","journal-title":"J Pharmacol Exp Ther"},{"issue":"9959","key":"179_CR25","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(14)60803-5","volume":"384","author":"A Vaclavkova","year":"2014","unstructured":"Vaclavkova A, Chimenti S, Arenberger P, Holl\u00f3 P, Sator P-G, Burcklen M, et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Lond Engl. 2014;384(9959):2036\u201345.","journal-title":"Lancet Lond Engl"},{"issue":"9959","key":"179_CR26","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/S0140-6736(14)61039-4","volume":"384","author":"C Ryan","year":"2014","unstructured":"Ryan C, Menter A. Ponesimod: a future oral therapy for psoriasis? Lancet. 2014;384(9959):2006\u20138.","journal-title":"Lancet"},{"issue":"5","key":"179_CR27","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","volume":"167","author":"P Gergely","year":"2012","unstructured":"Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167(5):1035\u201347.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"179_CR28","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1165\/rcmb.2006-0383OC","volume":"36","author":"F Roviezzo","year":"2007","unstructured":"Roviezzo F, Di Lorenzo A, Bucci M, Brancaleone V, Vellecco V, De Nardo M, et al. Sphingosine-1-phosphate\/sphingosine kinase pathway is involved in mouse airway hyperresponsiveness. Am J Respir Cell Mol Biol. 2007;36(6):757\u201362.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"179_CR29","first-page":"1","volume":"30","author":"ZZN Yiu","year":"2015","unstructured":"Yiu ZZN, Warren RB, Mrowietz U, Griffiths CEM. Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes. J Dermatol Treat. 2015;30:1\u20136.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"179_CR30","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/bjd.13060","volume":"171","author":"ZZN Yiu","year":"2014","unstructured":"Yiu ZZN, Griffiths CEM, Warren RB. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. Br J Dermatol. 2014;171(3):485\u201391.","journal-title":"Br J Dermatol"},{"issue":"5","key":"179_CR31","first-page":"AB162","volume":"70","author":"A Menter","year":"2014","unstructured":"Menter A, Disch D, Clemens J, Janes J, Papp K, Macias W. A phase 2b trial of baricitinib, an oral JAK inhibitor, in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2014;70(5):AB162.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"179_CR32","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjd.13745","volume":"173","author":"K Papp","year":"2015","unstructured":"Papp K, Pariser D, Catlin M, Wierz G, Ball G, Akinlade B, et al. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2015;173(3):767\u201376.","journal-title":"Br J Dermatol"},{"key":"179_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/09546634.2015.1115819","volume":"14","author":"R Bissonnette","year":"2016","unstructured":"Bissonnette R, Luchi M, Fidelus-Gort R, Jackson S, Zhang H, Flores R, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. J Dermatol Treat. 2016;14:1\u20137.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"179_CR34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1468-3083.2011.04078.x","volume":"26","author":"M David","year":"2012","unstructured":"David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky F, et al. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol JEADV. 2012;26(3):361\u20137.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"5","key":"179_CR35","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbamem.2010.12.017","volume":"1808","author":"CE M\u00fcller","year":"2011","unstructured":"M\u00fcller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011;1808(5):1290\u2013308.","journal-title":"Biochim Biophys Acta"},{"issue":"47","key":"179_CR36","doi-asserted-by":"crossref","first-page":"16814","DOI":"10.1073\/pnas.1414189111","volume":"111","author":"A Zanin-Zhorov","year":"2014","unstructured":"Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, Chen W, Scher JU, Mo R, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci USA. 2014;111(47):16814\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"179_CR37","unstructured":"Psoriasis (plaque, moderate to severe)\u2014apremilast [ID679] | Guidance and guidelines | NICE [Internet]. [cited 2015 Aug 5]. Available from https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-tag469\/documents ."},{"key":"179_CR38","unstructured":"Scottish Medicines Consortium apremilast (Otezla) CPP [Internet]. [cited 2015 Aug 5]. Available from https:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/1052_15_apremilast_Otezla_plaque_psoriasis\/apremilast_Otezla_plaque_psoriasis ."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-016-0179-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-016-0179-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-016-0179-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:28:36Z","timestamp":1559503716000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-016-0179-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,29]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["179"],"URL":"https:\/\/doi.org\/10.1007\/s40257-016-0179-3","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,29]]}}}